# Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

> **NCT05019794** · PHASE2 · UNKNOWN · sponsor: **LianBio LLC** · enrollment: 80 (estimated)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Solid Tumor

## Interventions

- **DRUG:** Infigratinib

## Key facts

- **NCT ID:** NCT05019794
- **Lead sponsor:** LianBio LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-13
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05019794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05019794, "Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05019794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*